HCPCS Code C9170

Injection, tarlatamab-dlle, 1 mg
Code effective Jan 01, 2025

HCPCS Section
Temporary Codes for Use with Outpatient Prospective Payment System

C9170 is a valid 2026 HCPCS code meaning Injection, tarlatamab-dlle, 1 mg or (Inj, tarlatamab-dlle, 1 mg) for short. HCPCS C9170 has been effective since 01/01/2025 and applies to Medical care.


HCPCS Code Details - C9170

HCPCS Level II Code
Section C - Temporary Codes for Use with Outpatient Prospective Payment System
HCPCS Code C9170
Description

Long description:
Injection, tarlatamab-dlle, 1 mg

Short description:
Inj, tarlatamab-dlle, 1 mg

HCPCS Pricing indicator 53 - Statute
Multiple pricing indicator A - Not applicable as HCPCS priced under one methodology
Statute number 1833(t)
Coverage code D - Special coverage instructions apply
BETOS2 code O1E - Other drugs
HCPCS Action code N - No maintenance for this code
Type of service 1 - Medical care
Effective date Effective Jan 01, 2025
Date added Added Oct 01, 2024
Termination date Dec 31, 2024

See also

  • HCPCS C9169 · Injection, nogapendekin alfa inbakicept-pmln, for intravesical use, 1 microgram

  • HCPCS J9026 · Injection, tarlatamab-dlle, 1 mg

  • HCPCS C9171 · Injection, pegulicianine, 1 mg

1 Two-digit numeric codes are Level I code modifiers copyrighted© by the American Medical Association's Current Procedural Terminology (CPT).

2 BETOS stands for “Berenson-Eggers Type Of Service”


HCPCS Level II codes and descriptors are approved and maintained jointly by the alpha-numeric editorial panel (consisting of CMS, the Health Insurance Association of America, and the Blue Cross and Blue Shield Association). — Updated 6/23/2026

CPT® is a registered trademark of the American Medical Association (AMA). All rights reserved.